The Conversation (0)
March 17, 2025
21 May 2024
Cleo Diagnostics
Revolutionising Ovarian Cancer Diagnosis Through Accurate and Early Detection Keep Reading...
27 February 2025
Appendix 4D and Half Yearly Accounts
Cleo Diagnostics (COV:AU) has announced Appendix 4D and Half Yearly AccountsDownload the PDF here. Keep Reading...
31 January 2025
Quarterly activities and cashflow report
Cleo Diagnostics (COV:AU) has announced Quarterly activities and cashflow reportDownload the PDF here. Keep Reading...
09 December 2024
CLEO Further Expands Ovarian Cancer Trial with Siles Health
Cleo Diagnostics (COV:AU) has announced CLEO Further Expands Ovarian Cancer Trial with Siles HealthDownload the PDF here. Keep Reading...
26 November 2024
The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial
Cleo Diagnostics (COV:AU) has announced The Royal Women's Hospital Joins CLEO Ovarian Cancer TrialDownload the PDF here. Keep Reading...
4h
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate at the upcoming TD Cowen... Keep Reading...
10 February
5 Small-cap Biotech ETFs to Watch
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one vehicle.ETFs are a popular choice as they allow investors to enter the market more safely... Keep Reading...
10 February
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of results from its Phase II ARCHER study... Keep Reading...
03 February
Seegnal Expands Deployment of Seegnal's Prescription Intelligence Platform at Tel Aviv Sourasky Medical Center, a Leading Israeli Public Medical Center and Global Referral Center
Seegnal Inc. (TSXV: SEGN), a global leader in clinical decision support solutions applying patient-centric medication safety standards, today announced its deepened partnership with Tel Aviv Sourasky Medical Center ("Sourasky Medical Center"). Israel's second-largest public hospital, Sourasky... Keep Reading...
23 January
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has closed its previously announced private... Keep Reading...
16 January
Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has entered into an agreement with a sole... Keep Reading...
Latest News
Interactive Chart
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00